Thus, targeting RAB39A-RXRB axis is a promising therapeutic approach to specifically affect the CSC fraction of the total cancer cell population that is also the tumor cell fraction associated with chemoresistance, recurrence, and metastasis. The gene discussed is RAB39A; the disease is cancer.